BENGALURU, Nov 3 (Reuters) - The World Health Organization (WHO) said on Wednesday that it has granted approval for Indian drugmaker Bharat Biotech's home-grown COVID-19 vaccine for emergency use listing, paving the way for it to be accepted as a valid vaccine in many poor countries.
The WHO tweeted that its technical advisory group had ruled that benefits of the shot, known as Covaxin, significantly outweighed the risks and that it met WHO standards for protection against COVID-19.
The decision had been delayed as the advisory group sought additional clarifications from Bharat Biotech before conducting a final risk-benefit assessment for the vaccine's global use.
WHO's Strategic Advisory Group of Experts on Immunization also recommended Covaxin's use in two doses, with an interval of four weeks, in age groups 18 and above. These recommendations are in line with the company's guidance.
Read More at https://www.reuters.com/world/india/whos-advisory-group-recommends-emergency-listing-indias-first-homegrown-covid-19-2021-11-03/
Comments